Alphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive

Funding and Investment - Isomorphic Labs has raised $600 million in external capital for the first time, led by Thrive Capital with participation from GV and Alphabet [1] - The funding will accelerate the development of Isomorphic's AI drug design engine and support the goal of bringing discovered drugs to clinical trials [1] Company Background - Isomorphic Labs was founded by DeepMind co-founder Demis Hassabis, leveraging DeepMind's software for AI drug discovery, including the AlphaFold model [2] - The company secured strategic partnerships with Eli Lilly and Novartis last year, potentially generating up to $3 billion in milestone payments for access to its AI model [2] Leadership and Recognition - Demis Hassabis stated that while Isomorphic Labs did not need the capital, the funding will assist in hiring top research scientists [3] - Hassabis and DeepMind researcher John Jumper received a Nobel Prize in chemistry in 2024 for their work on AlphaFold [3]